Zydus Company Profile

✉ Email this page to a colleague

ZYDUS has three hundred and sixty-four approved drugs.

There is one US patent protecting ZYDUS drugs. There are twenty-five tentative approvals on ZYDUS drugs.

There are four patent family members on ZYDUS drugs in four countries and nine hundred and seven supplementary protection certificates in eighteen countries.

International Patents:	4
US Patents:	1
Tradenames:	295
Ingredients:	286
NDAs:	364
Patent Litigation for Zydus:	See patent lawsuits for Zydus

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms Usa	RIBAVIRIN	ribavirin	TABLET;ORAL	077094-001	Dec 5, 2005	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Zydus Pharms Usa Inc	TOPIRAMATE	topiramate	TABLET;ORAL	078235-003	Mar 27, 2009	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Zydus Pharms	CLOBAZAM	clobazam	TABLET;ORAL	211449-002	Oct 22, 2018	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Zydus Pharms Usa Inc	ZOLMITRIPTAN	zolmitriptan	TABLET, ORALLY DISINTEGRATING;ORAL	202890-002	May 15, 2013	AB	RX	No	Yes		⤷ Try a Trial				⤷ Try a Trial
Zydus Pharms	FENTANYL-100	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	209655-008	Jan 24, 2023		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
India	651MU2014	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2015128877	⤷ Try a Trial
South Africa	201606075	⤷ Try a Trial
Philippines	12016501686	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2526934	132016000119245	Italy	⤷ Try a Trial	PRODUCT NAME: IBRUTINIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE PER IL TRATTAMENTO DI PAZIENTI ADULTI CON LEUCEMIA LINFOCITICA CRONICA (CLL) PRECEDENTEMENTE NON TRATTATA(IMBRUVICA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/945, 20160530
2443246	CR 2021 00036	Denmark	⤷ Try a Trial	PRODUCT NAME: ICOSAPENT ETHYL; REG. NO/DATE: EU/1/20/1524 20210329
2526934	CA 2016 00056	Denmark	⤷ Try a Trial	PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2016)3293 20160530
2487163	SPC/GB17/010	United Kingdom	⤷ Try a Trial	PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; REGISTERED: UK EU/1/15/1025/001 20150715; UK EU/1/15/1025/002 20150715
1028111	C300598	Netherlands	⤷ Try a Trial	PRODUCT NAME: MIRABEGRON EN ZOUTEN ERVAN; REGISTRATION NO/DATE: EU/1/12/809/001-014 20121220
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.